Novel Platform Technology for Allergy & Cancer Immunology Featured at Biotech Showcase 2016

Jan 14, 2016, 13:10 ET from Immunomic Therapeutics, Inc.

HERSHEY, Pa. and ROCKVILLE, Md., Jan. 14, 2016 /PRNewswire/ -- A unique vaccine technology, with applications in allergy and cancer immunology, was the focus of yesterday's talk from Eric Winzer, CFO at Immunomic Therapeutics, Inc. (ITI) at the 2016 Biotech Showcase™.

Winzer shared that LAMP-Vax™ is uniquely designed to educate, direct and focus the immune system to create a strong immune memory response. By enhancing the antigen presentation to the immune system, the platform is expected to offer significant value for allergy and cancer vaccines in development. Following a deal made late last year, the Japanese firm Astellas Pharma is developing a pipeline of allergy therapies based on LAMP-Vax, allowing for ITI to focus on cancer immunology.

"Immunotherapy drugs will be treating 60% of cancers in the next 10 years and LAMP-Vax is potentially a critical enabling technology," noted Eric Winzer, CFO at Immunomic Therapeutics, Inc. "At Immunomix, we've developed a diverse and robust pipeline and LAMP-Vax could be a key part of the new era of effective cancer vaccine treatments."

About LAMP-Vax platform
The LAMP-Vax platform is a breakthrough technology that has the potential to fundamentally improve the use of vaccines across a wide variety of diseases.  LAMP-Vax is a next-generation DNA vaccine that stimulates an immune response against a particular protein by injecting the DNA encoding the protein rather than the protein itself.  However, unlike older, conventional DNA vaccines, LAMP-Vax includes the DNA sequence encoding Lysosomal Associated Membrane Protein (LAMP).  This allows DNA vaccines developed, based on the LAMP-Vax platform, to utilize the body's natural biochemistry to develop a more complete immune response compared to conventional DNA vaccines.  Unlike conventional DNA vaccines that primarily elicit a cytotoxic T cell immune response, vaccines developed using LAMP-Vax initiate a more complete immune response, including antibody production, cytokine release and critical immunological memory.  The ability to activate a complete immune response gives LAMP-Vax technology potential across a number of diseases, including cancer immunotherapy, allergy and infectious diseases.

About Immunomic Therapeutics
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company dedicated to pioneering vaccines that transform lives.  Headquartered in Hershey, PA with lab facilities in Rockville, MD, ITI is developing next-generation vaccines based on patented LAMP Technology.  Its LAMP-Vax vaccine platform significantly increases the immune response to nucleic acid vaccines and simplifies vaccine design and delivery for safer, more cost-effective therapies.  LAMP constructs have been validated in human clinical trials for cancer and have been applied to targets like allergy, cancer and infectious diseases.  Immunomic Therapeutics' vision is to have regulatory approved products in pollen allergy, food allergy, cancer, and animal health. For information about Immunomic Therapeutics and LAMP Technology, visit www.immunomix.com.

 

SOURCE Immunomic Therapeutics, Inc.



RELATED LINKS

http://www.immunomix.com
http://www.immunomix.com